{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:46:58Z","timestamp":1790066818292,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clgc.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T19:47:38Z","timestamp":1372880858000},"page":"397-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Andrew J.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Kemeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L.","family":"Bitting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kartcheske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Embree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2013.05.007_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.05.007_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.007_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.05.007_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.007_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/pcan.2011.23","article-title":"Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer","volume":"14","author":"Antonarakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.007_bib6","article-title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor","volume":"30","author":"De Bono","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.007_bib7","doi-asserted-by":"crossref","unstructured":"Parker C, Heinrich D, O'Sullivan J, et\u00a0al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). ESMO\/ECCO 2011; (abstract 1LBA).","DOI":"10.1016\/S0959-8049(11)70100-9"},{"key":"10.1016\/j.clgc.2013.05.007_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2013.05.007_bib9","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-08-0125","article-title":"Targeting the PI3K\/AKT pathway for the treatment of prostate cancer","volume":"15","author":"Sarker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2005.11.042","article-title":"PTEN function in normal and neoplastic growth","volume":"241","author":"Chow","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clgc.2013.05.007_bib11","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Grunwald","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib12","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pros.10332","article-title":"Long-term androgen-ablation causes increased resistance to PI3K\/Akt pathway inhibition in prostate cancer cells","volume":"58","author":"Pfeil","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2013.05.007_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1073\/pnas.0510652103","article-title":"Pten deletion leads to the expansion of a prostatic stem\/progenitor cell subpopulation and tumor initiation","volume":"103","author":"Wang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clgc.2013.05.007_bib15","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2013.05.007_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2013.05.007_bib18","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib19","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clgc.2013.05.007_bib20","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","article-title":"Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts","volume":"15","author":"Fung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2013.05.007_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2013.05.007_bib23","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6605882","article-title":"Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR","volume":"103","author":"Schayowitz","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2013.05.007_bib24","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-4385","article-title":"Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib25","unstructured":"George DJ, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men withhormone-refractory metastatic prostate cancer (HRPC). Proc Am Soc Clin Oncol 2008; (abstract 181)."},{"key":"10.1016\/j.clgc.2013.05.007_bib26","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","article-title":"Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF","volume":"105","author":"Guba","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2013.05.007_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1432-2277.2004.00026.x","article-title":"Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer","volume":"18","author":"Guba","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.clgc.2013.05.007_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002112","article-title":"Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis","volume":"71","author":"Huber","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.clgc.2013.05.007_bib29","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.007_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2013.05.007_bib31","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.007_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2013.05.007_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1541-7786.MCR-10-0490","article-title":"Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers","volume":"9","author":"Armstrong","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2013.05.007_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/0008-5472.CAN-11-3004","article-title":"Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy","volume":"72","author":"Sun","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2013.05.007_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.007_bib38","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","article-title":"Dual inhibition of mTOR and estrogen receptor signaling in\u00a0vitro induces cell death in models of breast cancer","volume":"11","author":"Boulay","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib39","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clgc.2013.05.007_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clgc.2013.05.007_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.007_bib42","article-title":"Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC)","volume":"28","author":"Buckle","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.007_bib43","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2236","article-title":"Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance","volume":"16","author":"Tanaka","year":"2010","journal-title":"Nat Med"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.007_bib44","article-title":"Isolation of circulating tumor cells using a novel EMT-based capture method","volume":"30","author":"Bitting","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313001389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313001389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:50Z","timestamp":1761564170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767313001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1558767313001389"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.05.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}